What is Leerink Partnrs’ Forecast for MREO Q1 Earnings?

Mereo BioPharma Group plc (NASDAQ:MREO) – Equities research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Mereo BioPharma Group in a report issued on Monday, November 18th. Leerink Partnrs analyst J. Schwartz expects that the company will earn $0.00 per share for the quarter. Leerink Partnrs also issued estimates for Mereo BioPharma Group’s Q2 2025 earnings at $0.04 EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.02) EPS and FY2026 earnings at $0.00 EPS.

MREO has been the subject of a number of other research reports. Needham & Company LLC reissued a “buy” rating and issued a $7.00 price objective on shares of Mereo BioPharma Group in a research report on Tuesday, November 12th. Cantor Fitzgerald restated an “overweight” rating and set a $7.00 price target on shares of Mereo BioPharma Group in a research note on Tuesday, October 1st. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Mereo BioPharma Group has a consensus rating of “Buy” and an average price target of $7.50.

Mereo BioPharma Group Stock Up 4.8 %

NASDAQ MREO opened at $3.49 on Wednesday. The firm’s fifty day simple moving average is $4.20 and its two-hundred day simple moving average is $3.95. Mereo BioPharma Group has a 12-month low of $3.17 and a 12-month high of $5.02.

Insider Transactions at Mereo BioPharma Group

In other news, General Counsel Charles Sermon sold 9,980 shares of the stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $4.47, for a total value of $44,610.60. Following the sale, the general counsel now owns 240,007 shares in the company, valued at $1,072,831.29. This represents a 3.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Denise Scots-Knight sold 28,611 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $4.47, for a total transaction of $127,891.17. Following the transaction, the chief executive officer now directly owns 868,967 shares of the company’s stock, valued at approximately $3,884,282.49. This trade represents a 3.19 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 158,175 shares of company stock worth $702,832 over the last three months.

Institutional Investors Weigh In On Mereo BioPharma Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Frazier Life Sciences Management L.P. lifted its holdings in shares of Mereo BioPharma Group by 15.8% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 5,097,779 shares of the company’s stock valued at $20,952,000 after buying an additional 696,408 shares during the period. State Street Corp purchased a new position in Mereo BioPharma Group during the third quarter valued at approximately $195,000. Polar Asset Management Partners Inc. lifted its holdings in Mereo BioPharma Group by 36.0% in the third quarter. Polar Asset Management Partners Inc. now owns 198,300 shares of the company’s stock valued at $815,000 after acquiring an additional 52,500 shares during the period. Janus Henderson Group PLC boosted its position in Mereo BioPharma Group by 56.7% in the 3rd quarter. Janus Henderson Group PLC now owns 12,345,866 shares of the company’s stock worth $50,865,000 after purchasing an additional 4,464,984 shares in the last quarter. Finally, Fred Alger Management LLC grew its stake in shares of Mereo BioPharma Group by 108.1% during the 3rd quarter. Fred Alger Management LLC now owns 102,582 shares of the company’s stock worth $422,000 after purchasing an additional 53,278 shares during the period. 62.83% of the stock is owned by institutional investors and hedge funds.

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.